Haemonetics Corporation (HAE) News
Follow Haemonetics Corporation (HAE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 27 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Haemonetics Fiscal Q2 Adjusted Earnings and Revenue Rise
EQUITY | Nov 05, 2026, 12:02 PM UTC
M
Haemonetics Posts Fiscal Q2 Revenue of $357.8M
Fiscal Q2 revenue was $357.8M, versus the FactSet estimate of $345.1M.
EQUITY | Nov 05, 2026, 11:29 AM UTC
M
Haemonetics Reports Fiscal Second-Quarter Earnings
Haemonetics reported fiscal second-quarter earnings.
EQUITY | Nov 05, 2026, 11:28 AM UTC
M
Haemonetics Q2 Revenue and Adjusted EPS Beat Expectations
EQUITY | Nov 05, 2026, 11:26 AM UTC
M
Haemonetics Reports 2Q Revenue of $358M
EARNINGS | Nov 05, 2026, 11:13 AM UTC
M
Haemonetics Raises Fiscal 2027 Revenue Growth Forecast to 8%-11%
EARNINGS | Nov 05, 2026, 11:12 AM UTC
M
Haemonetics Reports 3Q 2026 Revenue of $357.76M and EPS of $1
The company’s second-quarter revenue, net income and operating income increased year over year, supported by volume growth and share gains in Plasma, MedSurg growth and other factors.
EARNINGS | Nov 05, 2026, 11:11 AM UTC
M
Haemonetics Announces Fiscal 2027 Second-Quarter Earnings Release Availability
EQUITY | Nov 05, 2026, 11:11 AM UTC
M
Haemonetics Posts Fiscal Q2 2027 Results on Investor Relations Website
The financial release and supplemental presentation are available online.
EQUITY | Nov 05, 2026, 11:02 AM UTC
M
Nasdaq Gains 1.11% as S&P 500 Rises; Dow Slips
The Nasdaq Composite rose 1.11% and the S&P 500 gained 0.66% on the session, while the Dow Jones Industrial Average slipped 0.07%.
EQUITY | Oct 19, 2026, 10:12 PM UTC
L
Haemonetics Receives FDA Approval for PerQseal Elite Vascular Closure System
The FDA approved the device for use in large-bore arterial procedures, Haemonetics said.
REGULATION | Oct 19, 2026, 09:01 PM UTC
L
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System
Haemonetics announced FDA approval of its PerQseal Elite Vascular Closure System.
REGULATION | Oct 19, 2026, 08:15 PM UTC
H
Haemonetics Stock Hits 52-Week High - Here's Why
Haemonetics Corporation (NYSE: HAE ) stock surged Thursday after the company disclosed that CSL Plasma Inc. plans to deploy its NexSys PCS devices with Persona PLUS technology across all its current U.S. plasma collectio
LIVE | Oct 08, 2026, 05:04 PM UTC
M
Haemonetics shares jump on expanded plasma device rollout
Haemonetics said it is expanding the rollout of plasma collection devices, with its stock up 17% to $119.56, on pace for its highest close since $116.97.
EQUITY | Oct 08, 2026, 02:10 PM UTC
H
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Thursday. Shares of Helen of Troy Limited (NASDAQ: HELE ) rose sharply after the company reported better-than-expected second-quarter adjuste
LIVE | Oct 08, 2026, 01:53 PM UTC
H
Haemonetics Q1 2027 Earnings Call Transcript
Haemonetics (NYSE: HAE ) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire ca
LIVE | Oct 05, 2026, 11:14 AM UTC
M
Haemonetics sets Nov. 5 date for Q2 FY2027 results
Haemonetics said it will publish second-quarter fiscal 2027 results on November 5, 2026.
EQUITY | Sep 30, 2026, 08:05 PM UTC
L
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strate
MNA | Sep 15, 2026, 12:33 PM UTC
L
Haemonetics maintained at Outperform by Raymond James
Raymond James maintains an Outperform rating on Haemonetics.
EQUITY | Sep 03, 2026, 06:36 PM UTC
L
Haemonetics signs CSL Plasma supply agreement, shares hit 52-week high
Haemonetics Corp. says it executed a non-exclusive supply agreement with CSL Plasma for NexSys PCS devices and Persona PLUS technology across CSL’s U.S. network, while leaving fiscal 2027 guidance unchanged.
EARNINGS | Aug 18, 2026, 05:12 PM UTC
H
AMLX jumps on Phase 3 LUCIDITY avexitide topline results
ALXN-backed ally?—No: AMLX is up about 29% after positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide, while HAE and BBWI also post gains and HD adds a 2% earnings move.
EARNINGS | Aug 18, 2026, 12:20 PM UTC
L
Haemonetics signs non-exclusive CSL Plasma supply agreement
Haemonetics says it will supply CSL Plasma with NexSys PCS devices featuring Persona PLUS technology and allow purchases of related disposables in the U.S., under a non-exclusive agreement with no minimum purchase commit
EARNINGS | Aug 18, 2026, 10:15 AM UTC
L
Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B Est
Haemonetics (NYSE: HAE ) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 billion-$1.441 billion vs $1.402 billion estimate.
EARNINGS | Aug 06, 2026, 10:02 AM UTC
L
HAE - Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website - Click For Rele
HAE - Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
EQUITY | Aug 06, 2026, 10:00 AM UTC
M
HAE: VASCADE MVP XL System Effective
HAE's VASCADE MVP XL System shows effectiveness
EQUITY | Aug 03, 2026, 08:15 PM UTC
L
HAE - Martin Madaus Elected to Haemonetics Board of Directors
HAE - Martin Madaus Elected to Haemonetics Board of Directors
EQUITY | Jul 28, 2026, 08:16 PM UTC
L
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
EQUITY | Jul 28, 2026, 11:29 AM UTC